GlassScriptPhysician profile
Donna Sillman
NPI 1841480282
$3,201.23
in general payments reported to CMS, 2019-2025
24 companies · $991 in 2025
The $991 reported for 2025 was more than what 96% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $665 · 2022: $451 · 2023: $827 · 2024: $266 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,084.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $530.98 | 2021-2025 | Yeztugo, Epclusa |
| Novo Nordisk INC | $430.61 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Astellas Pharma US INC | $382.13 | 2023-2025 | Veozah, Myrbetriq |
| Amgen INC. | $247.94 | 2021 | |
| Lilly USA, LLC | $179.73 | 2025 | Zepbound, Mounjaro |
| Abbvie INC. | $145.03 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $141.01 | 2022 | |
| Sumitomo Pharma America, INC. | $124.99 | 2023 | Myfembree |
| Xeris Pharmaceuticals, INC. | $122.88 | 2023 | Gvoke Hypopen |
| Biogen, INC. | $120.00 | 2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $103.92 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.70 | 2024 | Trulance |
| Pfizer INC. | $90.50 | 2023 | |
| Exeltis, USA INC. | $77.58 | 2022-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $75.24 | 2021-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $68.52 | 2022-2023 | Pifeltro, Dificid, Delstrigo |
| Therapeuticsmd, INC. | $52.29 | 2021 | |
| Mylan Pharmaceuticals INC. | $47.56 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $39.29 | 2021-2022 | |
| Evofem Biosciences, INC. | $37.64 | 2021 | |
| Organon LLC | $33.69 | 2022 | |
| Avion Pharmaceuticals | $28.01 | 2021 | |
| Mckesson Medical-Surgical, INC. | $15.00 | 2021 | |
| Hologic INC | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Sillman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.